INTRODUCTION {#s1}
============

Ewing sarcoma (ES) is a highly malignant tumor that originates in the bone and/or soft tissue. Although it is a rare cancer with an incidence reported of anywhere from one to three people diagnosed per million in a year ([@MCS004580FERC36]; [@MCS004580FERC17]; [@MCS004580FERC32]), it is the second most common primary malignancy of the bone following osteosarcoma ([@MCS004580FERC17]). The median age of diagnosis is 14--15 yr of age, although 20%--30% of cases are diagnosed in the first decade of life and cases continue to be diagnosed beyond the second decade with decreasing frequency ([@MCS004580FERC6]; [@MCS004580FERC32]; [@MCS004580FERC37]). Age is also a prognostic factor in this disease with individuals under the age of 15 having a better outcome than those 15 yr and older ([@MCS004580FERC31]).

Molecularly, ES is characterized by the presence of the *EWSR1* gene fusions with one of several genes from the E26 transformation-specific (ETS) family of transcription factors, such as *FLI1, ERG, ETV1, ETV4*, and *FEV* ([@MCS004580FERC15]; [@MCS004580FERC8]; [@MCS004580FERC22]; [@MCS004580FERC29]). ESWR1 is a member of the ten--eleven translocation (TET) family ([@MCS004580FERC45]) and in rare cases *FUS,* another member of the TET family ([@MCS004580FERC45]), can substitute for *EWSR1* ([@MCS004580FERC20]). Additionally, there is an emerging new molecular category---Ewing-like tumor---that is morphologically similar to ES but has *EWSR1* fusions involving non-ETS genes ([@MCS004580FERC34]) as well as fusions with genes other than ETS or TET family members (e.g., *CIC-DUX4*, *BCOR-CCNB3*) ([@MCS004580FERC13]; [@MCS004580FERC43]). Of the *EWSR1-*ETS fusions in ES, the *EWSR1-FLI1* fusion (t(11;22)(q24;q12)) is the most commonly detected and found in 85% of cases. The *EWSR1-ERG* fusion (t(21;22)(q22;q12)) is the next most common pairing, detected in anywhere from 5% to 10% of cases ([@MCS004580FERC20]).

To date, there are no clinically recognized hereditary cancer syndromes that predispose individuals to ES, although it has been a topic of investigation. One group described an increased incidence of neuroectodermal tumors and stomach cancer in relatives of patients with ES, although no causative genetic factor was identified ([@MCS004580FERC30]). A large case-control study that sequenced 1162 sarcoma probands, including 134 of the Ewing subtype, reported a significant association between germline mutations in FANC genes and sarcomas characterized by somatic translocations ([@MCS004580FERC4]). Other reported associations of germline mutations with ES include mutations in DNA repair pathway genes such as *TP53*, *PMS2*, and others, as well as known hereditary cancer syndrome genes such as *RET*, *PTCH2*, *ATM*, and others ([@MCS004580FERC48]; [@MCS004580FERC7]). ES has also rarely been described as a second malignancy in patients with heritable retinoblastoma ([@MCS004580FERC14]). Importantly, although these associations exist, there is little evidence demonstrating that these germline alterations played a pathogenic role in the development of ES.

Neurofibromatosis type 1 (NF-1) is an autosomal dominant hereditary cancer syndrome caused by germline loss-of-function mutations in the *NF1* gene, which encodes a RAS-GTPase-activating protein that functions as a negative regulator of Ras proteins ([@MCS004580FERC11]). It affects one in 2500--3500 individuals worldwide irrespective of sex or ethnic background and imparts a higher risk of developing tumors ([@MCS004580FERC24]). NF-1 patients develop a variety of tumors by inactivation of the remaining wild-type allele of *NF1*. Almost all individuals with NF-1 will develop pigmentary skin lesions, such as café au lait macules, axillary or inguinal freckling, and/or Lisch nodules. A subset of individuals also develops skeletal abnormalities, neurologic difficulties, cardiovascular abnormalities, and/or tumors. These tumors can be malignant or benign, with benign neurofibromas occurring in 99% of individuals ([@MCS004580FERC18]). The lifetime risk of cancer developing in patients with NF-1 is estimated to be ∼7% ([@MCS004580FERC24]). Optic pathway gliomas are the most common central nervous system (CNS) tumor seen in NF-1 patients ([@MCS004580FERC28]), but other CNS tumors also occur ([@MCS004580FERC030]). Additionally, non-CNS solid tumors, such as pheochromocytoma ([@MCS004580FERC47]) and breast cancer ([@MCS004580FERC40]), as well as hematologic malignancies have been reported ([@MCS004580FERC39]; [@MCS004580FERC24]).

A wide variety of sarcomas are associated with NF-1. Malignant peripheral nerve sheath tumors commonly occur arising from a plexiform or nodular neurofibroma. Less commonly, a wide variety of other sarcomas may occur including gastrointestinal stromal tumor (GIST) ([@MCS004580FERC25]), rhabdomysarcoma ([@MCS004580FERC19]), osteosarcoma, and leiomyosarcoma ([@MCS004580FERC2]; [@MCS004580FERC26]). We found one report of an NF-1 patient with ES ([@MCS004580FERC10]) and another NF-1 patient with a Ewing-like sarcoma driven by a *CIC-DUX4* fusion ([@MCS004580FERC46]).

Here we describe a 3-yr-old child with NF-1, who was diagnosed with *EWSR1-ERG* fusion--positive ES that also harbored a somatic mutation of *NF1* in addition to a germline nonsense mutation of *NF1*. The second hit on *NF1* suggests that biallelic inactivation of *NF1* provided a growth advantage to the tumor cells and highlights the potential role of Ras pathway mutations as secondary events in ES.

RESULTS {#s2}
=======

A previously healthy, 3-yr-old girl presented with a 3-wk history of back pain and an 8-wk history of tiptoe walking. Her mother reported a clinical diagnosis of NF-1 made in Mexico; she has overt multiple neurofibromas and café au lait spots on her face and arms. The patient had not been tested for *NF1* at the time of presentation. However, on physical examination she appeared to have a clinical diagnosis of NF-1: more than six café au lait spots and axillary freckling without overt neurofibromas ([@MCS004580FERC50]). She appeared uncomfortable and was febrile with an occasional cough on initial presentation. Auscultation was notable for decreased breath sounds over the left lung. Her neurological examination showed adequate movement of the lower extremities as well as muscle tone, but she refused to stand up and walk.

A chest radiograph demonstrated two densities in the left and right paraspinal region centered around T7, measuring 3.8 × 2.7 cm and 5.8 × 4.4 × 4.5 cm, respectively. A CT of the chest demonstrated a posterior mediastinal tumor of the mid-thoracic spine with bony destruction of T7 and tumor encroachment of the spinal cord, extending into the spinal canal from T6 to T8 ([Fig. 1](#MCS004580FERF1){ref-type="fig"}A--C).

![Diagnostic (*A*--*C*) and postinduction chemotherapy (*D*--*F*) MRI. (*A*) Coronal, (*B*) sagittal, and (*C*) axial views demonstrating paraspinal tumor with the displacement of the aorta and esophagus anteriorly and encroachment of the left and right hilar and bronchi as well as the left atrium and pulmonary veins. The estimated tumor volume was calculated at 720 mm^3^. (*D*) Coronal, (*E*) sagittal, and (*F*) axial views demonstrating good response to induction chemotherapy. Estimated tumor volume is 120 mm^3^, which represents an 84% reduction of baseline tumor size.](MCS004580Fer_F1){#MCS004580FERF1}

A biopsy of the mass showed a highly cellular, high-grade neoplasm composed of sheets of plump spindle cells in short fascicles alternating with fibrovascular septa ([Fig. 2](#MCS004580FERF2){ref-type="fig"}A). The tumor cells contained scant cytoplasm, large round nuclei with vesicular chromatin and prominent nucleoli. Focal perivascular areas contained smaller round cells with conspicuous nuclear molding ([Fig. 2](#MCS004580FERF2){ref-type="fig"}B). Mitotic activity was brisk (more than 20 mitotic figures/10 high-power fields). Immunohistochemistry revealed the cells to be positive for synaptophysin in a perivascular distribution ([Fig. 2](#MCS004580FERF2){ref-type="fig"}C), whereas SOX10 was positive in scattered smaller spindle cells dispersed throughout the spindle cell areas ([Fig. 2](#MCS004580FERF2){ref-type="fig"}D). In addition, tumor cells were positive for vimentin, CD99 ([Fig. 2](#MCS004580FERF2){ref-type="fig"}F), and neuron-specific enolase (NSE) with retained BAF47 expression (not shown). Conversely, no staining for keratins, CD45, muscle-specific actin, smooth muscle actin, desmin, epithelial membrane antigen, chromogranin, or glial fibrillary acid protein (GFAP) was identified. H3K27Me3 showed a mosaic pattern of expression ([Fig. 2](#MCS004580FERF2){ref-type="fig"}E). Although the histology of the tumor was consistent with ES, FISH analysis of the tumor specimen showed no structural rearrangements associated with ES, although gains of 12q13.1 (*FOXO1*), 18q11.2 (*SS18*), and 22q12 (*EWSR1*) were observed ([Supplemental Table 2)](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004580/-/DC1). Further diagnostic classification was therefore sought by utilizing a targeted sequencing panel specifically designed to evaluate selected exons and introns for cancer-relevant genes and a subset of known fusions ([@MCS004580FERC27]). DNA was extracted from tumor and blood. Panel testing revealed a truncating mutation of *NF1* (p.K2396\*) in the tumor and an inactivating *NF1* mutation that was also present in the blood sample (p.Y2285\*) ([Table 1](#MCS004580FERTB1){ref-type="table"}; [Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004580/-/DC1)), likely resulting in biallelic inactivation of *NF1*. In addition, the tumor harbored an *EWSR1-ERG* fusion, confirming the diagnosis of ES ([Table 1](#MCS004580FERTB1){ref-type="table"}; [Fig. 3](#MCS004580FERF3){ref-type="fig"}). No other pathogenic variants were detected in the submitted tumor specimen.

![(*A*) The tumor was composed of short fascicles of plump spindle cells. (*B*) The tumor cells had scant cytoplasm, large nuclei with vesicular chromati, and brisk mitotic activity (arrows). Clusters of rounder cells with nuclear molding were observed around vessels (arrowhead). (*C*) Synaptophysin was expressed in a perivascular pattern in the round cells. (*D*) SOX10 showed staining in scattered smaller cells. (*E*) H3K27Me3 immunohistochemistry showed a patchy (so-called "mosaic") pattern of H3K27Me expression. The dot-like staining in most cells represents inactivated X chromosome(s) ([@MCS004580FERC38]). Multiple such signals in some nuclei may represent X-chromosome duplication. (*F*) CD99 expression. (A) Original magnification, 100×; (*B*--*E*) original magnification, 200×; (*F*) original magnification, 40×.](MCS004580Fer_F2){#MCS004580FERF2}

![Integrated Genome Viewer snapshot of the chimeric read pairs mapping to intron 7 of *ERG* on Chromosome 21 (genomic position indicated by red arrow at ideogram at *top*) and intron 8 of *EWSR1* and on Chromosome 22 (genomic position indicated by red arrow at ideogram at *top*). The blue boxes at the *bottom* indicate the position of exons 6, 7, and 8 of *ERG* and 8 and 9 of *EWSR1*. The sequencing assay tiles over introns 5--13 of *EWSR1* and all its exons. Only exons of *ERG* are captured and are not shown in the *left* panel because of the height of the chimeric read pile over *ERG* intron 7. Reads are colored by insert size. The gray reads over *ESWR1* at the *bottom* of the *right* panel show the unrearranged background reads over the captured region of *ESWR1*.](MCS004580Fer_F3){#MCS004580FERF3}

###### 

Variant table

  Gene            Chr      HGVS DNA reference   HGVS protein reference   Variant type   Predicted effect   dbSNP/dbVar ID   Genotype or allele frequency   ClinVar ID
  --------------- -------- -------------------- ------------------------ -------------- ------------------ ---------------- ------------------------------ --------------
  Blood sample                                                                                                                                             
   *NF1*          17       c.6855C\>A           p.Y2285\*                Nonsense       Pathogenic         rs772295894      Heterozygous                   185082
  Tumor tissue                                                                                                                                             
   *NF1*          17       c.7186A\>T           p\. K2396\*              Nonsense       Pathogenic         Not reported     37% allele frequency           Not reported
   *NF1*                   c.6855C\>A           p.Y2285\*                Nonsense       Pathogenic         rs772295894      57% allele frequency           185082
   *EWSR1, ERG*   22, 21   t(21;22)(q22;q12)    EWSR1-ERG                Fusion         Pathogenic         Not applicable   Not available                  Not reported

Pending sequencing results, Ewing therapy with concurrent radiation therapy was started after surgical resection of the tumor using an interval-compression chemotherapy consisting of vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide given the tumor histologically appeared to be consistent with ES and because of the rapidly evolving cord compression. The patient tolerated chemotherapy well and after two cycles of chemotherapy the tiptoe walking resolved. Evaluation of response at the end of six cycles of induction chemotherapy showed dramatic improvement in the intraspinal tumor. Measurements of the right and left paraspinous thoracic tumor showed a \>80% decrease in volume compared to baseline ([Fig. 1](#MCS004580FERF1){ref-type="fig"}D--F). The patient completed treatment and is currently doing well 3 mo after completion of therapy.

DISCUSSION {#s3}
==========

Ewing sarcoma in patients with NF-1 has been reported only once in the literature ([@MCS004580FERC10]), although in that report there was no characterization of the type of ES fusion or *NF1* mutations. In the case reported here, an *EWSR1-ERG* fusion was detected by a next-generation sequencing (NGS) assay but not by FISH. False-negative results using dual break-apart probes for the detection of the *EWSR1-ERG* fusion can occur because of the complex nature of this rearrangement ([@MCS004580FERC9]).

Mechanistically, *EWSR1-*ETS fusions exert their oncogenic affect by driving dramatic changes in the transcriptome of cells harboring the fusion ([@MCS004580FERC16]). Receptor tyrosine kinases (RTKs) have been shown to have higher transcript expression levels in ES tumors ([@MCS004580FERC33]), and as the Ras pathway is a major effector of downstream signaling for RTKs, it may represent an important mediator of the oncogenic effects of *EWSR1* fusions. IGFR1 is a well-established RTK that has been shown to be essential in this capacity ([@MCS004580FERC21]). In support of this, inhibition of the Ras pathway through MEK1/2 inhibitors has been shown to suppress malignant phenotypes in ES cell lines ([@MCS004580FERC42]; [@MCS004580FERC5]). Additionally, two independent studies reported down-regulation of *SPRY1* and miRNA *let-7*, both negative regulators of RAS, in ES cell lines resulting in Ras pathway activation ([@MCS004580FERC23]; [@MCS004580FERC12]). It is interesting to speculate that as Ras is a main converging point for downstream signaling of activated RTKs up-regulated in ES, the acquisition of mutations or implementation of other molecular mechanisms that can result in Ras pathway activation may be advantageous to ES cells. NF1 is one such target as it is a negative regulator of the Ras pathway, where it catalyzes the hydrolysis of Ras-bound guanosine triphosphate (GTP) to guanine diphosphate (GDP) and keeps Ras in the active state ([@MCS004580FERC11]).

The patient presented here had two *NF1* mutations. The germline *NF1* p.Y2285\* (c.6855C\>A) found in the patient described here is a known pathogenic variant associated with NF-1 ([Table 1](#MCS004580FERTB1){ref-type="table"}; ClinVar ID 185082). The somatic nonsense mutation p.K2396\* seen in this patient has been reported in a single sample of a grade IV astrocytoma (COSM5766195). It is not present in ClinVar or LOVD but is predicted to result in protein truncation and classified as a PVS1 according to ACMG guidelines ([@MCS004580FERC35]). The two nonsense mutations affected different exons so that they could not be phased. However, we also observed a large deletion of Chromosome 17, where *NF1* resides in the tumor ([Fig. 4](#MCS004580FERF4){ref-type="fig"}). One possible explanation for this observation is that the tumor is polyploid and duplicate copies of the wild-type *NF1* gene were removed by two independent events---the tumor-specific p.K2396\* mutation and loss of a chromosome. Although polyploidy was originally suggested by the *EWSR1* FISH results showing copy-number increase of the locus ([Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004580/-/DC1)), chromosome analysis ([Supplemental Fig. 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004580/-/DC1)) subsequently revealed a normal female complement with no abnormal clones detected. An alternative explanation is the presence of heterogeneity in the tumor. The second hit somatic mutation in *NF1* was present at an allele frequency of 37%, which could suggest a subclonal nature to this mutation. Although not definitive, the two nonsense mutations in *NF1* in conjunction with the Chromosome 17 deletion encompassing *NF1* favor a model of biallelic inactivation and reduces the likelihood that NF1 inactivation is happening by chance in this tumor; biallelic inactivation of *NF1* suggests that there was a selective advantage to losing the wild-type allele and that *NF1* is contributing to sarcomagenesis.

![Genome-wide copy-number changes. The *y*-axis shows the log~2~ ratio of normalized ratio of copy-number changes in the tumor to a reference genome with 0 corresponding to no copy-number change. The *x*-axis shows the genome from Chromosome 1 to Chromosome Y. The *upper* panel shows the copy number across the genome; the *lower* panel shows the variant allele frequency.](MCS004580Fer_F4){#MCS004580FERF4}

Mutations in Ras pathway genes have only infrequently been reported in ES ([@MCS004580FERC41]; [@MCS004580FERC49]). Querying the GENIE cBioPortal database (v5.0) confirmed the paucity of Ras pathway mutations in ES, with only four cases of 143 ES patients in whose tumors mutated Ras pathway genes were detected ([@MCS004580FERC1]).

This case highlights several important aspects of the evaluation of solid tumors and the role of NGS analysis in their evaluation. First, it demonstrates that NGS can sometimes identify pathogenic fusions events not detected by standard methods. In this particular case, NGS testing was used to confirm the diagnosis of ES. This highlights the potential utility of NGS, although it should be noted that access to this technology continues to be limited, especially in middle- and low-income countries. Other immunohistochemistry-based tests may be useful for confirming ES in patients ([@MCS004580FERC3]). Second, it demonstrates the utility of NGS analysis in tumors from patients with inherited cancer predispositions, as it can evaluate the role of the inherited predisposition in the pathogenesis of specific cancer under study. In the case reported here, NGS clearly demonstrated a likely role for the inherited predisposition because the tumor acquired a second hit in the same gene. Last, this case underscores the underappreciated role of the Ras pathway in the pathogenesis and progression of ES.

METHODS {#s4}
=======

NGS Testing {#s4a}
-----------

Genomic DNA was extracted from tumor tissue that had been macrodissected from formalin-fixed, paraffin-embedded blocks and blood. Capture-based next-generation DNA sequencing was performed as previously described at the UCSF Clinical Cancer Genomics Laboratory, using an assay that targets all coding exons of 479 cancer-related genes, *TERT* promoter, select introns, and upstream regulatory regions of 47 genes ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004580/-/DC1)) to enable detection of structural variants including gene fusions and DNA segments at regular intervals along each chromosome to enable genome-wide copy-number and zygosity analysis, with a total sequencing footprint of 2.8 Mb. Sequencing libraries were prepared from genomic DNA, and target enrichment was performed by hybrid capture using a custom oligonucleotide library (Roche NimbleGen). Sequencing was performed on an Illumina HiSeq 2500. Tumors are sequenced to an average unique depth coverage of approximately \>500×. Duplicate sequencing reads were removed computationally to allow for accurate allele frequency determination and copy-number calling. The analysis was based on the human reference sequence (NCBI build 37) using the following software packages: BWA 0.7.13, Samtools 1.1 (using htslib 1.1), Picard tools 1.97 (1504), GATK Appistry v2015.1.1-3.4.46-0-ga8e1d99, CNVkit 0.7.2, Pindel 0.2.5b8, SATK Appistry v2015.1.1-1-gea45d62, ANNOVAR v2016Feb01, FreeBayes 0.9.20, and Delly 0.7.2.13-20 Single-nucleotide variants, insertions/deletions, and structural variants were visualized and verified using the Integrated Genome Viewer. Genome-wide copy-number analysis based on on-target and off-target reads was performed by CNVkit ([@MCS004580FERC44]) and visualized with Nexus Copy Number (Biodiscovery). See [Supplemental Table 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004580/-/DC1) for sequencing coverage details.

FISH Testing {#s4b}
------------

FISH testing was performed by the Pathology Department at Valley Children\'s Hospital in Madera, California according to standard protocols. Probes for detecting the EWSR1 fusion were from Abbott Molecular.

Histopathology {#s4c}
--------------

Four micrometer sections of formalin-fixed paraffin-embedded tissue were stained with hematoxylin and eosin. Immunostaining and detection were performed on a Leica Bond III automated immunostainer using primary antibodies, clones, dilutions and sources, respectively: synaptophysin (polyclonal; 1:100, Cell-Marque), SOX10 (EP268, 1:250 Cell-Marque), CD99 (EPR3097Y, 1:100, Cell-Marque), H3K27Me3 (C36B11, 1:50, Cell Signaling Technology). Synaptophysin was done to investigate the presence of neuroendocrine differentiation---SOX10 for nerve sheath/melanocytic differentiation and CD99 as a sensitive, but not specific, stain for ES.

ADDITIONAL INFORMATION {#s5}
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